Association between age and the initiation of antihypertensive, lipid lowering and antiplateletet medications in elderly individuals newly treated with antidiabetic drugs

Age and Ageing

Volumn 38, Issue 6, 2009, Pages 741-745

  Sirois, Caroline ^a,b   Moisan, Jocelyne ^a   Poirier, Paul ^c   Couture, Julie ^a   Gregoire, Jean Pierre ^a  

^a LAVAL UNIVERSITY   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; GROWTH HORMONE SECRETAGOGUE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT;

AGING; CARDIOVASCULAR DISEASE; COMORBIDITY; DIABETES MELLITUS; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; LETTER; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOTONIC AGENTS; COHORT STUDIES; DIABETES MELLITUS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; ODDS RATIO; PLATELET AGGREGATION INHIBITORS;

EID: 70350701874     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afp170     Document Type: Letter

References (26)

1. Millar WJ, Young TK. Tracking diabetes: Prevalence, incidence and risk factors. Health Rep 2003; 14: 35-47.
2. Poirier P, Desprès JP, Bertrand O. Identifying which patients with diabetes should be tested for the presence of coronary heart disease - the importance of baseline electrocardiogram and exercise testing. Can J Cardiol 2006; 22(Suppl A): 9-15.
3. Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care 2002; 25: 471-5.
4. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
5. Collins R, Armitage J, Parish S et al. MRC/BHF Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
6. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
7. Canadian Diabetes Association. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27(Suppl 2): S1-152.
8. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008; 31(Suppl 1): S12-54.
9. IDF Clinical Guidelines Task Force. GlobalGuideline for Type 2 Diabetes. Brussels, IL: International Diabetes Federation, 2005.
10. Usher C, Bennett K, Feely J. Evidence for a gender and age inequality in the prescribing of preventative cardiovascular therapies to the elderly in primary care.Age Ageing 2004; 33: 500-2.
11. Glynn R, Monane M, Gurwitz JH, Choodnovskiy I, Avron J. Aging, comorbidity, and reduced rates of drug treatment for diabetes mellitus. J Clin Epidemiol 1999; 52: 781-90.
12. Palnum KD, Petersen P, Sorensen HT et al. Older patients with acute stroke in Denmark: Quality of care and short-term mortality. A nationwide follow-up study. Age Ageing 2008; 37: 90-5.
13. Brophy MT, Snyder KE, Gaehde S, Ives C, Gagnon D, Fiore LD. Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc 2004; 52: 1151-6.
14. Boucher JM, Racine N, Thanh TH et al. Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarction. CMAJ 2001; 164: 1285-90.
15. Raum E, Lietzau S, Stegmaier C, Brenner H, Rothenbacher D. For the majority of patients with diabetes blood pressure and lipid management is not in line with recommendations. Results from a large population-based cohort in Germany. Pharmacolepidemiol Drug Saf 2008; 17: 485-94.
16. Egger SS, Rätz Bravo AE, Hess L, Schlienger RG, Krähenbühl S. Age-related differences in the prevalence of potential drugdrug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 2007; 24: 429-40.
17. Jacobson TA. Overcoming 'ageism' bias in the treatment of hypercholesterolaemia: A review of safety issues with statins in the elderly. Drug Saf 2006; 29: 421-48.
18. Lally F, Crome P. Understanding frailty. Postgrad Med J 2007; 83: 16-20.
19. Sirois C, Poirier P,Moisan J,Gr'egoire JP. The benefit of aspirin therapy in type 2 diabetes: What is the evidence? Int J Cardiol 2008; 129: 172-9.
20. American Diabetes Association. Standards of medical care in diabetes - 2007 (position statement). Diabetes Care 2007; 30(Suppl 1): S4-41.
21. Lindholm LH, Hansson L, Ekbom T et al. STOP Hypertension- 2 Study Group. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 2000; 18: 1671-5.
22. Rosen AB. Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002. J Gen Intern Med 2006; 21: 315-9.
23. Alter DA, Stukel TA, Newman A. Proliferation of cardiac technology in Canada: A challenge to the sustainability of Medicare. Circulation 2006; 113: 380-7.
24. Gerber Y, Rihal CS, Sundt TM et al. Coronary revascularization in the community. A population-based study, 1990 to 2004. J Am Coll Cardiol 2007; 50: 1223-9.
25. Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older.NEngl J Med 2008; 358: 1887-98.
26. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623-30.